DK3630847T3 - Adamts-bindende immunglobuliner - Google Patents

Adamts-bindende immunglobuliner Download PDF

Info

Publication number: DK3630847T3
Authority: DK; Denmark
Prior art keywords: immunglobulins; adamts; binding; binding immunglobulins
Prior art date: 2017-06-02

Application number

DK18730689.9T

Other languages

English (en)

Inventor

Marie-Ange Buyse

Guy Hermans

Sven Lindemann

Hans Guehring

Ralf Guenther

Roland Kellner

Original Assignee

Merck Patent Gmbh

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-02

Filing date

2018-06-04

Publication date

2024-12-02

2018-06-04 Application filed by Merck Patent Gmbh, Ablynx Nv filed Critical Merck Patent Gmbh

2024-12-02 Application granted granted Critical

2024-12-02 Publication of DK3630847T3 publication Critical patent/DK3630847T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Bipolar Transistors (AREA)

DK18730689.9T 2017-06-02 2018-06-04 Adamts-bindende immunglobuliner DK3630847T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP17174403		2017-06-02
PCT/EP2018/064665 WO2018220234A1 (en)	2017-06-02	2018-06-04	Adamts binding immunoglobulins

Publications (1)

Publication Number	Publication Date
DK3630847T3 true DK3630847T3 (da)	2024-12-02

Family

ID=59014502

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18730689.9T DK3630847T3 (da)	2017-06-02	2018-06-04	Adamts-bindende immunglobuliner

Country Status (22)

Country	Link
US (3)	US11261260B2 (da)
EP (2)	EP4272822A3 (da)
JP (2)	JP7758459B2 (da)
KR (2)	KR102752550B1 (da)
CN (2)	CN118894939A (da)
AU (2)	AU2018277343B2 (da)
BR (1)	BR112019024333A2 (da)
CA (1)	CA3063293A1 (da)
DK (1)	DK3630847T3 (da)
ES (1)	ES3002733T3 (da)
FI (1)	FI3630847T3 (da)
HR (1)	HRP20241562T1 (da)
HU (1)	HUE068952T2 (da)
IL (1)	IL270908B1 (da)
LT (1)	LT3630847T (da)
MX (1)	MX2019014400A (da)
PL (1)	PL3630847T3 (da)
PT (1)	PT3630847T (da)
RS (1)	RS66191B1 (da)
SI (1)	SI3630847T1 (da)
TW (1)	TWI802576B (da)
WO (1)	WO2018220234A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
DK2723769T4 (da)	2011-06-23	2022-09-05	Ablynx Nv	Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
IL270908B1 (en)	2017-06-02	2026-04-01	Merck Patent Gmbh	ADAMTS-binding immunoglobulins
US20240027467A1 (en) *	2019-12-20	2024-01-25	Vib Vzw	Nanobody Exchange Chromatography
AU2022266254A1 (en) *	2021-04-30	2023-12-14	Merck Patent Gmbh	Methods for the administration of adamts binding immunoglobulins
US11970548B2 (en) *	2021-08-27	2024-04-30	Innovative Cellular Therapeutics Holdings, Ltd.	Nanobody target GCC and uses in chimeric antigen receptor cell therapy

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB335768A (en)	1929-10-24	1930-10-02	Jacoviac Maurice	Improvements in protecting devices for gramophone disc records
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
SE509359C2 (sv)	1989-08-01	1999-01-18	Cemu Bioteknik Ab	Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
AU701578B2 (en)	1992-08-21	1999-02-04	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
WO1994025591A1 (en)	1993-04-29	1994-11-10	Unilever N.V.	PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
EP0702721B1 (en)	1993-06-09	2001-01-03	Unilever N.V.	Process for producing fusion proteins comprising scfv fragments by a transformed mould
FR2708622B1 (fr)	1993-08-02	1997-04-18	Raymond Hamers	Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es)	1996-06-27	2008-04-01	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw.	Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
BR9813276A (pt)	1997-10-27	2000-08-22	Unilever Nv	Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
WO1999037681A2 (en)	1998-01-26	1999-07-29	Unilever Plc	Method for producing antibody fragments
AU3295299A (en)	1998-02-19	1999-09-06	Xcyte Therapies, Inc.	Compositions and methods for regulating lymphocyte activation
EP0967284A1 (en)	1998-05-28	1999-12-29	Pfizer Limited	Phosphodiesterases
BR9916765A (pt)	1999-01-05	2001-09-25	Unilever Nv	Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico
DE60013767T3 (de)	1999-01-19	2009-07-09	Unilever N.V.	Verfahren zur herstellung von antikörperfragmenten
CA2361678A1 (en)	1999-02-05	2000-08-10	Rijksuniversiteit Leiden	Method of modulating metabolite biosynthesis in recombinant cells
US6617122B1 (en)	1999-03-15	2003-09-09	Xenon Genetics, Inc.	Process for identifying modulators of ABC1 activity
CN1252264C (zh)	1999-04-22	2006-04-19	荷兰联合利华有限公司	利用单价抗原－结合蛋白抑制病毒感染
SG121853A1 (en)	1999-06-18	2006-05-26	Cv Therapeutics Inc	Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
EP1198572A2 (en)	1999-08-02	2002-04-24	Keygene N.V.	Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
US6391610B1 (en)	1999-08-06	2002-05-21	The Cleveland Clinic Foundation	Nucleic acids encoding zinc metalloproteases
GB9922124D0 (en)	1999-09-17	1999-11-17	Pfizer Ltd	Phosphodiesterase enzymes
US6479280B1 (en)	1999-09-24	2002-11-12	Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de)	1999-11-18	2001-05-23	Bayer Ag	GABA-B-Rezeptoren
DE60042789D1 (de)	1999-11-29	2009-10-01	Bac Ip B V	Immobilisierte antigenbindende moleküle aus einer domäne
AU1859201A (en)	1999-11-29	2001-06-12	Unilever Plc	Immobilisation of proteins
EP2180054A1 (en)	1999-12-24	2010-04-28	Genentech, Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
ES2324280T3 (es)	2000-03-14	2009-08-04	Unilever N.V.	Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
WO2001090190A2 (en)	2000-05-26	2001-11-29	National Research Council Of Canada	Single-domain antigen-binding antibody fragments derived from llama antibodies
US20020151702A1 (en)	2000-10-18	2002-10-17	Genetics Institute, Inc.	Aggrecanase molecules
PL362008A1 (en)	2000-10-20	2004-10-18	Genetics Institute, Llc.	Novel aggrecanase molecules
WO2002042439A2 (en)	2000-10-27	2002-05-30	Genetics Institute, Llc	Aggrecanase adamts9
ATE513854T1 (de)	2000-12-13	2011-07-15	Bac Ip B V	Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
US7211395B2 (en)	2001-03-09	2007-05-01	Dyax Corp.	Serum albumin binding moieties
DK1399484T3 (da)	2001-06-28	2010-11-08	Domantis Ltd	Dobbelt-specifik ligand og anvendelse af denne
US20060073141A1 (en)	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
EP1433793A4 (en)	2001-09-13	2006-01-25	Inst Antibodies Co Ltd	METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US20030105313A1 (en)	2001-10-16	2003-06-05	American Home Products Corporation	Aggrecanase molecules
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
EP1456410A2 (en)	2001-12-11	2004-09-15	AlgoNomics N.V.	Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en)	2001-12-21	2004-09-15	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Method for cloning of variable domain sequences
WO2003055527A2 (en)	2002-01-03	2003-07-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Immunoconjugates useful for treatment of tumours
US7521543B2 (en)	2002-10-23	2009-04-21	Ludwig Institute For Cancer Research	A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same
WO2005044858A1 (en)	2003-11-07	2005-05-19	Ablynx N.V.	Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004041867A2 (en)	2002-11-08	2004-05-21	Ablynx N.V.	Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
CA2505316C (en)	2002-11-08	2014-08-05	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004060965A2 (en)	2002-12-31	2004-07-22	Nektar Therapeutics Al, Corporation	Hydrolytically stable maleimide-terminated polymers
EP1587838B1 (en)	2003-01-10	2015-04-15	Ablynx N.V.	Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
US7461263B2 (en)	2003-01-23	2008-12-02	Unspam, Llc.	Method and apparatus for a non-revealing do-not-contact list system
CN1845938B (zh)	2003-06-30	2010-05-26	杜门蒂斯有限公司	多肽
AU2003264053A1 (en)	2003-08-12	2005-03-10	William M. Yarbrough	Treatment for acne vulgaris and method of use
WO2005061459A1 (en) *	2003-12-04	2005-07-07	Wyeth	Biaryl sulfonamides and methods for using same
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en)	2004-10-13	2006-04-20	Ablynx N.V.	Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2005325801A1 (en)	2005-01-31	2006-08-03	Ablynx N.V.	Method for generating variable domain sequences of heavy chain antibodies
WO2006122787A1 (en)	2005-05-18	2006-11-23	Ablynx Nv	Serum albumin binding proteins
ES2852423T3 (es)	2005-05-20	2021-09-13	Ablynx Nv	NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
EP2057191A1 (en)	2006-08-18	2009-05-13	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CA2671581A1 (en)	2006-12-05	2008-06-12	Ablynx N.V.	Peptides capable of binding to serum proteins
EP2102244A2 (en) *	2006-12-19	2009-09-23	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
JP2010518839A (ja)	2007-02-21	2010-06-03	アブリンクスエン．ヴェー．	血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド
CN101796072B (zh)	2007-05-24	2014-09-24	埃博灵克斯股份有限公司	用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
US20110183861A1 (en)	2008-01-29	2011-07-28	Ablynn N.V.	Methods to stabilize proteins and polypeptides
EP2268668A1 (en)	2008-04-17	2011-01-05	Ablynx N.V.	Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2011026948A1 (en)	2009-09-03	2011-03-10	Ablynx N.V.	Stable formulations of polypeptides and uses thereof
US9265834B2 (en)	2009-03-05	2016-02-23	Ablynx N.V.	Stable formulations of polypeptides and uses thereof
NZ595461A (en)	2009-04-10	2013-01-25	Ablynx Nv	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
ES2551854T3 (es)	2009-04-30	2015-11-24	Ablynx N.V.	Procedimiento para la producción de anticuerpos de dominio
CN102482700A (zh) *	2009-07-02	2012-05-30	葛兰素集团有限公司	多肽和治疗方法
PT3501499T (pt)	2010-02-11	2022-11-22	Ablynx Nv	Métodos e composições para a preparação de aerossóis
EP3590950A1 (en)	2011-05-09	2020-01-08	Ablynx NV	Method for the production of immunoglobulin single varible domains
DK2723769T4 (da)	2011-06-23	2022-09-05	Ablynx Nv	Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
EP2650310B1 (en)	2012-04-13	2016-06-08	Rottapharm Biotech S.r.l.	Anti-ADAMTS-5 antibody, derivatives and uses thereof
AU2014214325B2 (en) *	2013-02-06	2018-06-07	Merck Patent Gmbh	Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
CN105814082A (zh)	2013-09-26	2016-07-27	埃博灵克斯股份有限公司	双特异性纳米抗体
HUE067047T2 (hu) *	2013-10-15	2024-09-28	Genefrontier Corp	Humán antitest aggrekanáz típusú ADAMTS specieszek ellen aggrekanázzal kapcsolatos betegségek terápiájára
PL3248986T3 (pl)	2014-05-16	2022-05-16	Ablynx Nv	Domeny zmienne immunoglobuliny
AU2015336954A1 (en)	2014-10-22	2017-06-08	Katholieke Universiteit Leuven Ku Leuven Research & Development	Modulating adipose tissue and adipogenesis
EP3262068A1 (en)	2015-02-05	2018-01-03	Ablynx N.V.	Nanobody dimers linked via c-terminally engineered cysteins
TW202428621A (zh)	2017-06-02	2024-07-16	德商麥克專利有限公司	與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
IL270908B1 (en)	2017-06-02	2026-04-01	Merck Patent Gmbh	ADAMTS-binding immunoglobulins
IT201800003818A1 (it)	2018-03-21	2019-09-21	Fond Per Listituto Oncologico Di Ricerca Ior	Nuovi farmaci prosenescenza

2018
- 2018-06-04 IL IL270908A patent/IL270908B1/en unknown
- 2018-06-04 BR BR112019024333-0A patent/BR112019024333A2/pt unknown
- 2018-06-04 RS RS20241271A patent/RS66191B1/sr unknown
- 2018-06-04 TW TW107119218A patent/TWI802576B/zh active
- 2018-06-04 CN CN202410787210.3A patent/CN118894939A/zh active Pending
- 2018-06-04 PL PL18730689.9T patent/PL3630847T3/pl unknown
- 2018-06-04 HR HRP20241562TT patent/HRP20241562T1/hr unknown
- 2018-06-04 FI FIEP18730689.9T patent/FI3630847T3/fi active
- 2018-06-04 PT PT187306899T patent/PT3630847T/pt unknown
- 2018-06-04 KR KR1020197038469A patent/KR102752550B1/ko active Active
- 2018-06-04 JP JP2019566819A patent/JP7758459B2/ja active Active
- 2018-06-04 US US16/617,885 patent/US11261260B2/en active Active
- 2018-06-04 ES ES18730689T patent/ES3002733T3/es active Active
- 2018-06-04 KR KR1020257000333A patent/KR20250011229A/ko active Pending
- 2018-06-04 SI SI201831176T patent/SI3630847T1/sl unknown
- 2018-06-04 WO PCT/EP2018/064665 patent/WO2018220234A1/en not_active Ceased
- 2018-06-04 AU AU2018277343A patent/AU2018277343B2/en active Active
- 2018-06-04 CA CA3063293A patent/CA3063293A1/en active Pending
- 2018-06-04 MX MX2019014400A patent/MX2019014400A/es unknown
- 2018-06-04 CN CN201880036462.5A patent/CN111032695B/zh active Active
- 2018-06-04 LT LTEPPCT/EP2018/064665T patent/LT3630847T/lt unknown
- 2018-06-04 DK DK18730689.9T patent/DK3630847T3/da active
- 2018-06-04 EP EP23184254.3A patent/EP4272822A3/en active Pending
- 2018-06-04 HU HUE18730689A patent/HUE068952T2/hu unknown
- 2018-06-04 EP EP18730689.9A patent/EP3630847B1/en active Active
2022
- 2022-01-19 US US17/579,345 patent/US12209136B2/en active Active
2023
- 2023-05-30 JP JP2023088623A patent/JP2023123448A/ja active Pending
2024
- 2024-12-16 US US18/983,096 patent/US20250257145A1/en active Pending
2025
- 2025-04-04 AU AU2025202424A patent/AU2025202424A1/en active Pending

Also Published As

Publication number	Publication date
IL270908B1 (en)	2026-04-01
AU2025202424A1 (en)	2025-04-24
RS66191B1 (sr)	2024-12-31
PL3630847T3 (pl)	2025-02-03
KR20200012935A (ko)	2020-02-05
EP4272822A3 (en)	2024-03-27
US20220289860A1 (en)	2022-09-15
JP2023123448A (ja)	2023-09-05
US20200317802A1 (en)	2020-10-08
HUE068952T2 (hu)	2025-02-28
CN111032695A (zh)	2020-04-17
EP4272822A2 (en)	2023-11-08
US11261260B2 (en)	2022-03-01
RU2019143075A3 (da)	2021-11-12
LT3630847T (lt)	2024-12-10
BR112019024333A2 (pt)	2020-07-28
TW201920287A (zh)	2019-06-01
EP3630847B1 (en)	2024-09-04
AU2018277343A1 (en)	2020-01-02
CN118894939A (zh)	2024-11-05
JP2020525410A (ja)	2020-08-27
PT3630847T (pt)	2024-11-21
US12209136B2 (en)	2025-01-28
HRP20241562T1 (hr)	2025-01-31
FI3630847T3 (fi)	2024-12-05
ES3002733T3 (en)	2025-03-07
SI3630847T1 (sl)	2025-03-31
TWI802576B (zh)	2023-05-21
RU2019143075A (ru)	2021-07-13
CA3063293A1 (en)	2018-12-06
EP3630847A1 (en)	2020-04-08
AU2018277343B2 (en)	2025-01-23
JP7758459B2 (ja)	2025-10-22
IL270908A (en)	2020-01-30
KR102752550B1 (ko)	2025-01-10
WO2018220234A1 (en)	2018-12-06
KR20250011229A (ko)	2025-01-21
CN111032695B (zh)	2024-06-25
US20250257145A1 (en)	2025-08-14
MX2019014400A (es)	2020-02-10

Publication	Publication Date	Title
DK3731771T3 (da)	2023-08-28	V462033dk00
CL2018000524S1 (es)	2018-10-05	Golilla
EP3589248A4 (en)	2021-01-06	CRYOTHERAPIES
DE202018003363U8 (de)	2019-01-24	Handgelenkssphygmomanometer
EP3634404C0 (en)	2024-11-20	PYRAZOLE-BASED MAGL INHIBITORS
EP3588580A4 (en)	2020-12-02	SCHOTTKY MOS TRENCH DIODE
DK3351526T3 (da)	2021-02-08	Diisopentylterephthalat
EP3654852A4 (en)	2020-06-17	TOURNIQUET
EP3634397A4 (en)	2021-03-17	HETEROCYCLYL POLYMETHINE-BASED IR CHROMOPHORES
DK3568655T3 (da)	2023-04-17	Rekuperator
DK3571580T5 (da)	2021-11-08	Load-logical-and-shift-guarded-instruktion
DK3612237T3 (da)	2021-12-06	Genterapi
EP3611402A4 (en)	2020-04-15	SERVO CYLINDER
EP3615471A4 (en)	2021-01-06	PLASMA PHOTOELECTRONIC IMMUNE SENSOR
DK3630847T3 (da)	2024-12-02	Adamts-bindende immunglobuliner
EP3669219C0 (en)	2024-08-14	NETWORK SCALE
DK3576686T3 (da)	2022-01-03	Brokbind
DK3568506T3 (da)	2021-03-01	Offeranode
DK3510051T3 (da)	2020-03-16	Carboxylalkylchitosan
DK3676276T3 (da)	2022-02-21	Spirothietannukleosider
DK3395159T3 (da)	2020-02-24	Ballepresse
DK3576718T3 (da)	2021-08-23	Pastil
EP3618835A4 (en)	2021-03-17	APRAMYCIN DERIVATIVES
DK3391733T3 (da)	2020-03-16	Ballepresse
EP3575349A4 (en)	2020-02-19	RESIN FILM BASED ON VINYLIDENE FLUORIDE